{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelocytic%2C+Acute&page=10",
    "query": {
      "condition": "Leukemia, Myelocytic, Acute",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 2409,
    "total_pages": 241,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelocytic%2C+Acute&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelocytic%2C+Acute&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T08:52:06.543Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01685606",
      "title": "Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mantle Cell Lymphoma",
        "Diffuse Large Cell Lymphoma",
        "Burkitts Lymphoma",
        "T Cell Lymphomas",
        "Acute Myeloid Leukemia/Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "cellular immunotherapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2013-03",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2022-03-04",
      "last_synced_at": "2026-11-19T08:52:06.543Z",
      "location_count": 2,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01685606"
    },
    {
      "nct_id": "NCT05735184",
      "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Mixed Lineage Leukemia Gene Mutation",
        "Refractory AML",
        "AML With Mutated NPM1",
        "Acute Myeloid Leukemia Recurrent",
        "Acute Myeloid Leukemia, in Relapse",
        "NPM1 Mutation",
        "KMT2Ar",
        "Myeloid Sarcoma",
        "Nucleophosmin 1-mutated Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Ziftomenib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Quizartinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kura Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2023-07-18",
      "completion_date": "2030-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-11-19T08:52:06.543Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05735184"
    },
    {
      "nct_id": "NCT05326516",
      "title": "A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed/Refractory Leukemias",
        "Acute Lymphoblastic Leukemia",
        "Acute Lymphocytic Leukemia",
        "Mixed Phenotype Acute Leukemia",
        "Acute Myeloid Leukemia",
        "Acute Undifferentiated Leukemia"
      ],
      "interventions": [
        {
          "name": "Revumenib",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy Regimen 1",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy Regimen 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syndax Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Days",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Days and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-03-09",
      "completion_date": "2024-07-29",
      "has_results": false,
      "last_update_posted_date": "2024-08-13",
      "last_synced_at": "2026-11-19T08:52:06.543Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Boston, Massachusetts • Kansas City, Missouri + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05326516"
    },
    {
      "nct_id": "NCT06811233",
      "title": "Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "DMSA",
          "type": "DRUG"
        },
        {
          "name": "Ca-EDTA",
          "type": "DRUG"
        },
        {
          "name": "Magnesium Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Multivitamin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2025-05-08",
      "completion_date": "2031-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-19T08:52:06.543Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06811233"
    },
    {
      "nct_id": "NCT01253447",
      "title": "AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Recurrent Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Akt inhibitor MK2206",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2010-10",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2018-08-27",
      "last_synced_at": "2026-11-19T08:52:06.543Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01253447"
    },
    {
      "nct_id": "NCT06158100",
      "title": "Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Donor Lymphocyte Infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Antonio M Jimenez Jimenez",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 2,
      "start_date": "2024-12-04",
      "completion_date": "2026-06-02",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-11-19T08:52:06.543Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06158100"
    },
    {
      "nct_id": "NCT00590187",
      "title": "Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Sapacitabine, Arm A",
          "type": "DRUG"
        },
        {
          "name": "Sapacitabine, Arm B",
          "type": "DRUG"
        },
        {
          "name": "Sapacitabine, Arm C",
          "type": "DRUG"
        },
        {
          "name": "Sapacitabine, Arm D",
          "type": "DRUG"
        },
        {
          "name": "sapacitabine, Arm E",
          "type": "DRUG"
        },
        {
          "name": "sapacitabine, Arm F",
          "type": "DRUG"
        },
        {
          "name": "Sapacitabine, Arm G",
          "type": "DRUG"
        },
        {
          "name": "Sapacitabine, Arm H",
          "type": "DRUG"
        },
        {
          "name": "Sapacitabine, Arm I",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cyclacel Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2007-12",
      "completion_date": "2018-12-01",
      "has_results": true,
      "last_update_posted_date": "2024-06-04",
      "last_synced_at": "2026-11-19T08:52:06.543Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00590187"
    },
    {
      "nct_id": "NCT01826214",
      "title": "Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemias"
      ],
      "interventions": [
        {
          "name": "LDE225",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2013-05",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2016-08-30",
      "last_synced_at": "2026-11-19T08:52:06.543Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01826214"
    },
    {
      "nct_id": "NCT01036009",
      "title": "A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemia",
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Biphenotypic Leukemia",
        "Pre-leukemic Syndromes",
        "Monosomy 7",
        "Bone Marrow Clonal Malformations",
        "Juvenile Myelomonocytic Leukemia",
        "Myelodysplastic Syndromes",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Withdrawal of immunosuppression and donor lymphocyte infusion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "6 Months to 25 Years"
      },
      "enrollment_count": 43,
      "start_date": "2009-10",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-06-23",
      "last_synced_at": "2026-11-19T08:52:06.543Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • St. Petersburg, Florida",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01036009"
    },
    {
      "nct_id": "NCT00718159",
      "title": "Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Essential Thrombocythemia"
      ],
      "interventions": [
        {
          "name": "LY573636-sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2008-08",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-11-19T08:52:06.543Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00718159"
    }
  ]
}